DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and unaudited financial results for the quarter ended March 31, 2020 and also provided a corporate update.
First Quarter 2020 Financial Highlights
"We are pleased with how our messaging and user-experience are resonating with clinicians and patients, which is reflected in the strong sample volume and revenue growth we experienced during the first two and a half months of the first quarter, before the initial effects of the coronavirus pandemic. While the coronavirus pandemic has impacted our business near term, our long-term growth prospects remain strong and we believe may be enhanced by the broad movement of healthcare toward telemedicine services," said John Dobak, M.D., chief executive officer of DermTech. "We recently introduced a telemedicine solution for remote, clinician-guided sample collection by the patient for our non-invasive genomic melanoma rule-out test (the DermTech Pigmented Lesion Assay or DermTech PLA). While we do not expect this telemedicine option to immediately make up for testing volume lost due to stay-at-home orders, we believe this is an important long-term business strategy. By informing dermatologists of the option to serve patients through remote, clinician-guided, sample collection, we leverage the ease of use of our platform and create a new driver for potential business growth."
Corporate Update on COVID-19 Effects and Responses
We have initiated a broad COVID-19 response to drive education and usage despite reduced patient office visits and in-person sales calls. Although most dermatology offices are currently closed, our lab is fully operational, and we are receiving and analyzing samples. In response to the closure of dermatology offices, our sales team has been utilizing virtual sales calls and client education, and we have introduced a telemedicine option for remote, clinician-guided sample collection by the patient for the DermTech PLA test. We have implemented additional safety measures and social distancing within our commercial laboratory operations and have transitioned our administrative functions to working remotely. Although it is still too early to estimate the speed or extent of a recovery, some dermatology practices are reopening, particularly in states that are beginning to relax stay-at-home orders. We expect these reopened dermatology practices may focus initially on essential and time-sensitive dermatology care needs, such as skin cancer assessment, though it is not clear how this will impact our sample volumes. Other activities and effects related to the COVID-19 crisis are detailed below.
First Quarter 2020 Review
First Quarter 2020 Financial Results
Assay revenue increased 238% to $0.8 million for the three months ended March 31, 2020, compared to $0.2 million for the same period of 2019. Assay revenue for the three months ended March 31, 2020 increased due to higher billable sample volume and revenue recognition of Medicare samples related to the final local coverage determination effective February 10, 2020, compared to the same period of 2019. Contract revenue increased 111% to $0.8 million for the three months ended March 31, 2020, compared to $0.4 million for the same period of 2019. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers' clinical trial progress, which can be difficult to forecast due to variability of patient enrollment, drug safety and efficacy and other factors. Total revenues increased 161% to $1.6 million for the three months ended March 31, 2020, compared to $0.6 million for the same period in 2019.
Gross margin for the three months ended March 31, 2020 was 23%, compared to -6% for the same period of 2019. The increase in gross margin was largely driven by the increase in the Company's contract revenue during the three months ended March 31, 2020. Assay gross margin for the three months ended March 31, 2020 was -46%.
Sales and marketing expense increased 241% to $2.9 million for the three months ended March 31, 2020, compared to $0.9 million for the same period of 2019. The increase was primarily attributable to sales force expansion to drive the adoption of the DermTech PLA and additional marketing investment to increase awareness of the DermTech PLA as a non-invasive genomic based diagnostic for melanoma.
Research and development expense increased 57% to $0.9 million for the three months ended March 31, 2020, compared to $0.6 million for the same period of 2019. The increase was primarily attributable to higher compensation and recruiting costs related to expanding the research and development team as well as increased laboratory supplies.
General and administrative expense increased 130% to $3.5 million for the three months ended March 31, 2020, compared to $1.5 million for the same period of 2019. The increase was primarily due to additional public company costs, including higher audit and legal costs related to filings with the Securities and Exchange Commission, higher compensation costs from expanding the general and administrative team and higher insurance costs.
Net loss for the three months ended March 31, 2020 was $7.0 million, which included $1.0 million of non-cash stock-based compensation, compared to a net loss of $5.2 million for the same period of 2019, which included $0.3 million of non-cash stock-based compensation.
Cash and cash equivalents totaled $67.9 million as of March 31, 2020.
About DermTech:
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at: www.DermTech.com.
Forward-looking Statement
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the nature and duration of the effects of the COVID?19 pandemic and the effectiveness of DermTech's response thereto; changes in patient behavior and market conditions; patient and physician adoption of telemedicine and the effectiveness of the DermTech PLA administered via telemedicine; DermTech's expansion plans; the performance, patient benefits, cost-effectiveness and commercialization of DermTech's products and the market opportunity therefor; and the rate of development of DermTech's product pipeline. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech's ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech's tests; (4) the reimbursement of DermTech's tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech's products; (6) DermTech's ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech's products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the "Risk Factors" section of the most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10?Q filed by DermTech with the Securities and Exchange Commission (the "SEC"), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
DERMTECH, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) |
||||||||
|
|
March 31, 2020 |
|
December 31, 2019 |
||||
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
67,922 |
|
|
$ |
15,374 |
|
Accounts receivable |
|
|
1,175 |
|
|
|
680 |
|
Inventory |
|
|
75 |
|
|
|
35 |
|
Prepaid expenses and other current assets |
|
|
892 |
|
|
|
1,061 |
|
Total current assets |
|
|
70,064 |
|
|
|
17,150 |
|
Property and equipment, net |
|
|
1,736 |
|
|
|
977 |
|
Other assets |
|
|
167 |
|
|
|
84 |
|
Total assets |
|
$ |
71,967 |
|
|
$ |
18,211 |
|
Liabilities, Convertible Preferred Stock and Stockholders' Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,561 |
|
|
$ |
1,609 |
|
Accrued compensation |
|
|
1,120 |
|
|
|
1,142 |
|
Accrued liabilities |
|
|
200 |
|
|
|
218 |
|
Deferred revenue |
|
|
1,093 |
|
|
|
1,390 |
|
Deferred underwriting fees |
|
|
1,363 |
|
|
|
1,363 |
|
Total current and total liabilities |
|
|
5,337 |
|
|
|
5,722 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Series A convertible preferred stock, $0.0001 par value per share; 1,250 Series A shares authorized as of March 31, 2020 and December 31, 2019; 1,231 shares issued and outstanding at March 31, 2020 and December 31, 2019; $6.9 million and $7.6 million liquidation preference at March 31, 2020 and December 31, 2019 |
|
|
? |
|
|
|
? |
|
Series B-1 convertible preferred stock, $0.0001 par value per share; 3,200 and zero Series B-1 shares authorized as of March 31, 2020 and December 31, 2019; 3,199 and zero shares issued and outstanding at March 31, 2020 and December 31, 2019; $36.0 million and zero liquidation preference at March 31, 2020 and December 31, 2019 |
|
|
? |
|
|
|
? |
|
Series B-2 convertible preferred stock, $0.0001 par value per share; 525 and zero Series B-2 shares authorized as of March 31, 2020 and December 31, 2019; 524 and zero shares issued and outstanding at March 31, 2020 and December 31, 2019; $5.9 million and zero liquidation preference at March 31, 2020 and December 31, 2019 |
|
|
? |
|
|
|
? |
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 14,899,701 and 12,344,818 shares issued and outstanding at March 31, 2020 and December 31, 2019 |
|
|
1 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
164,741 |
|
|
|
103,599 |
|
Accumulated deficit |
|
|
(98,112 |
) |
|
|
(91,111 |
) |
Total stockholders' equity |
|
|
66,630 |
|
|
|
12,489 |
|
Total liabilities, convertible preferred stock and stockholders' equity |
|
$ |
71,967 |
|
|
$ |
18,211 |
|
DERMTECH, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (Unaudited) |
||||||||
|
|
Three Months Ended March 31, |
||||||
|
|
2020 |
|
2019 |
||||
Revenues: |
|
|
|
|
|
|
|
|
Assay revenue |
|
$ |
796 |
|
|
$ |
235 |
|
Contract revenue |
|
|
761 |
|
|
|
361 |
|
Total revenues |
|
|
1,557 |
|
|
|
596 |
|
Cost of revenues |
|
|
1,203 |
|
|
|
635 |
|
Gross profit/(loss) |
|
|
354 |
|
|
|
(39 |
) |
Operating expenses: |
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
2,944 |
|
|
|
864 |
|
Research and development |
|
|
897 |
|
|
|
572 |
|
General and administrative |
|
|
3,514 |
|
|
|
1,528 |
|
Total operating expenses |
|
|
7,355 |
|
|
|
2,964 |
|
Loss from operations |
|
|
(7,001 |
) |
|
|
(3,003 |
) |
Other expense: |
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
? |
|
|
|
(1,968 |
) |
Other expense |
|
|
? |
|
|
|
(185 |
) |
Total other expense |
|
|
? |
|
|
|
(2,153 |
) |
Net loss and comprehensive loss |
|
$ |
(7,001 |
) |
|
$ |
(5,156 |
) |
Weighted average shares outstanding used in computing net loss per share, basic and diluted |
|
|
13,100,642 |
|
|
|
4,411,279 |
|
Net loss per common share outstanding, basic and diluted |
|
$ |
(0.53 |
) |
|
$ |
(1.17 |
) |
These press releases may also interest you
|